

Japan Tobacco Inc. Clinical development (as of October 31, 2005)

| Code              | Stage                           | Indication     | Mechanism           | Characteristics  | Development                        | Rights  |
|-------------------|---------------------------------|----------------|---------------------|--|------------------------------------|---|
| JTT-705<br>(oral) | Phase1(JPN)                     | Dyslipidemia   | CETP inhibitor      | Decreases LDL and increases HDL by inhibition of CETP<br>-CETP:Cholesteryl Ester Transfer Protein, facilitates transfer of cholesteryl ester from HDL to LDL<br>-HDL:High density lipoprotein, Good Cholesterol<br>-LDL:Low density lipoprotein, Bad Cholesterol | Developed by JT                    | A license agreement was signed with Roche (Switzerland) for development and commercialization of this compound worldwide except Japan and Korea. (October 2004) |
| JTT-130<br>(oral) | Phase2(JPN)<br>Phase1(Overseas) | Hyperlipidemia | MTP inhibitor       | Treatment of hyperlipidemia by reducing absorption of cholesterol and triglyceride via inhibition of MTP<br>MTP:Microsomal Triglyceride Transfer Protein   | Developed by JT<br>Developed by JT |   |
| JTK-303<br>(oral) | Phase1(JPN)                     | Anti-HIV       | Integrase inhibitor | Integrase inhibitor which works by blocking integrase, an enzyme that is involved in the replication of HIV (HIV:Human Immunodeficiency Virus)   | Developed by JT                    | A license agreement was signed with Gilead (US) for development and commercialization of this compound worldwide except Japan . (March 2005)                    |
| JTT-302<br>(oral) | Phase1(Overseas)                | Dyslipidemia   | CETP inhibitor      | Decreases LDL and increases HDL by inhibition of CETP<br>-CETP:Cholesteryl Ester Transfer Protein, facilitates transfer of cholesteryl ester from HDL to LDL<br>-HDL:High density lipoprotein, Good Cholesterol<br>-LDL:Low density lipoprotein, Bad Cholesterol | Developed by JT                    |   |
| JTT-305<br>(oral) | Phase1(JPN)                     | Osteoporosis   | CaSR antagonist     | Increases BMD and decreases new vertebral fractures by accelerating endogenous PTH secretion via antagonism of circulating Ca on CaSR in parathyroid cells<br>-BMD: Bone Mineral Density<br>-PTH: Parathyroid Hormone<br>-CaSR: Calcium-Sensing Receptor         | Developed by JT                    |   |

Changes from the previous announcement on August 1, 2005:

Development of JTE-607 was terminated.